Precision BioSciences Inc (DTIL)
6.50
-0.68
(-9.47%)
USD |
NASDAQ |
Nov 21, 16:00
6.60
+0.10
(+1.54%)
Pre-Market: 09:01
Precision BioSciences Debt to Equity Ratio: 0.3434 for Sept. 30, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| September 30, 2024 | 0.3434 |
| June 30, 2024 | 0.3011 |
| March 31, 2024 | 0.6037 |
| December 31, 2023 | 1.188 |
| September 30, 2023 | 0.7695 |
| June 30, 2023 | 0.6556 |
| March 31, 2023 | 0.5543 |
| December 31, 2022 | 0.3677 |
| September 30, 2022 | 0.2628 |
| June 30, 2022 | 0.2147 |
| March 31, 2022 | 0.0356 |
| December 31, 2021 | 0.0272 |
| Date | Value |
|---|---|
| September 30, 2021 | 0.0242 |
| June 30, 2021 | 0.0242 |
| March 31, 2021 | 0.00 |
| December 31, 2020 | 0.00 |
| September 30, 2020 | 0.00 |
| June 30, 2020 | 0.00 |
| March 31, 2020 | 0.00 |
| December 31, 2019 | 0.00 |
| September 30, 2019 | 0.00 |
| June 30, 2019 | 0.00 |
| March 31, 2019 | 4.842 |
| December 31, 2018 | 0.00 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
Dec 2019
1.188
Maximum
Dec 2023
0.2686
Average
0.1252
Median
Debt to Equity Ratio Benchmarks
| Pfizer Inc | 0.7219 |
| Assembly Biosciences Inc | 0.00 |
| Protagonist Therapeutics Inc | 0.00 |
| Alector Inc | 0.00 |
| Entrada Therapeutics Inc | 0.00 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 153.26M |
| Total Liabilities (Quarterly) | 88.39M |
| Shareholders Equity (Quarterly) | 64.87M |
| Current Ratio | 9.224 |
| Net Debt Paydown Yield | 0.01% |